Affiliation:
1. Biomedical Research and Therapeutic Vaccines Institute
2. Icahn School of Medicine at Mount Sinai
3. Venezuelan Science Incubator
4. University of Minnesota Medical School
5. Universidad del Rosario (CIMBIUR), Universidad del Rosario
6. University of Oriente – Bolivar Nucleus
7. Fundación Universitaria Autónoma de Las Américas – Institución Universitaria Visión de Las Américas
Abstract
Abstract
Background Persistent headache is a frequent symptom after coronavirus disease 2019 (COVID-19) and there is currently limited knowledge about its clinical spectrum and predisposing factors. A subset of patients may be experiencing new daily persistent headache (NDPH) after COVID-19, which is among the most treatment-refractory primary headache syndromes.Methods We conducted a cross-sectional study in Latin America to characterize individuals with persistent headache after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and identify risk factors associated with NDPH. Participants over 18 years old who tested positive for SARS-CoV-2 infection and reported persistent headache among their symptoms completed an online survey that included demographics, past medical history, persistent headache clinical characteristics, and COVID-19 vaccination status. Based on participants’ responses, NDPH diagnostic criteria were used to group participants into NDPH and non-NDPH groups.Results Four hundred and twenty-one participants from 11 Latin American countries met the inclusion criteria. One in four participants met the diagnostic criteria for NDPH. The mean age was 40 years, with most participants being female (82%). Over 90% of the participants reported having had mild/moderate COVID-19. Most participants had a history of headache before developing COVID-19 (58%), mainly migraine type (32%). The most predominant clinical characteristics in the NDPH group were occipital location, severe/unbearable intensity, burning character, and radiating pain (p < 0.05). A higher proportion of anxiety symptoms, sleep problems, myalgia, mental fog, paresthesia, nausea, sweating of the face or forehead, and ageusia or hypogeusia as concomitant symptoms were reported in participants with NDPH (p < 0.05). Palpebral edema as a concomitant symptom during the acute phase of COVID-19, occipital location, and burning character of the headache were risk factors associated with NDPH.Conclusion This is the first study in Latin America that explored the clinical spectrum of NDPH after SARS-CoV-2 infection and its risk factors. Clinical evaluation of COVID-19 patients presenting with persistent headache should take into consideration NDPH.
Publisher
Research Square Platform LLC